NACDS president and CEO Steve Anderson is calling on Congress to prioritize consumer health and safety, and to help stamp out organized retail crime before year’s end.
The approval means that pharmacists will be allowed to switch out Lantus (insulin glargine) for the Semglee (insulin glargine-yfgn) biosimilar without the required approval from the prescribing physician.
The program can provide access to lifesaving treatments, and allowing pharmacists to prescribe and dispense will make it more effective and accessible for millions of Americans.